Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AIM Kanghuai Biological Technology, a subsidiary of AIM Vaccine Co., Ltd., is a Chinese biopharmaceutical company specializing in the research, development, and manufacturing of human vaccines. The company is best known for its Salk-strain inactivated poliovirus vaccine (sIPV), which is a critical component of global polio eradication efforts. Operating out of a large-scale manufacturing facility in Taizhou's China Medical City, AIM Kanghuai focuses on high-quality production standards to meet both domestic and international demand. Its business model integrates R&D with large-scale industrialization, positioning it as a key player in the Chinese vaccine market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AIM Kanghuai Biological Technology.